Vicus Therapeutics, Inc. (Vicus)

Oncology Corporate Profile

HQ Location

55 Madison Avenue, Suite 400
Morristown, NJ 7960

Company Description

Vicus Therapeutics is an immuno-oncology company bringing breakthrough immunotherapies to patients with solid-tumor cancers. Vicus' lead drug product, VT-122, is a novel combination of etodolac and propranolol and is the first immunotherapy to inhibit both prostaglandin and beta-adrenergic signaling to the immune system


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VT-122 (+ sorafenib)prostaglandin E2 inhibitorHepatocellular carcinoma (HCC)II
VT-122 (+ chemotherapy)prostaglandin E2 inhibitorLung cancerPreclinical
VT-122 (+ nab-paclitaxel and gemcitabine)prostaglandin E2 inhibitorPancreatic cancerPreclinical
VT-122 (+ 2nd generation angrodgen blockade)prostaglandin E2 inhibitorProstate cancerPreclinical
VT-122 (+ targeted chemotherapy)prostaglandin E2 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display